AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31574881 — intervention group
Group type: COMPARATOR
Intervention: Continuous adductor canal block (ACB)
Number of subjects: 0
Study 27558768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.0‐1.5 g/day for 6 months, then 0.5‐0.75 g/day for another 6 months
Number of subjects: 60
Study 27558768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 60
Study 25886930 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated services (ANC, prevention of mother-to-child transmission, and HIV care delivered in the ANC clinic)
Number of subjects: 611
Study 25886930 — intervention group
Group type: COMPARATOR
Intervention: Standard ANC services (including prevention of mother-to-child transmission and referral to a separate clinic for HIV care)
Number of subjects: 611
Study 25886930 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated services
Number of subjects: 611
Study 25886930 — intervention group
Group type: COMPARATOR
Intervention: Standard ANC services
Number of subjects: 611
Study 23538168 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once a day for 7 days
Number of subjects: 346
Study 23538168 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once a day for 7 days
Number of subjects: 346
Study 23538168 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Number of subjects: 346
Study 23538168 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 346
Study 21329626 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) dexibuprofen (450 mg, b.i.d.)
Number of subjects: 22
Study 21329626 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) dexibuprofen (300 mg, t.i.d.)
Number of subjects: 22
Study 19118394 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-mediated intervention program
Number of subjects: 0
Study 19118394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17728965 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 60
Study 17728965 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 60
Study 16623000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg
Number of subjects: 120
Study 16623000 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 120
Study 12452208 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 12452208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Budesonide and Terbutaline)
Number of subjects: 0
Study 12452208 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 0
Study 12452208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9652764 — intervention group
Group type: COMPARATOR
Intervention: FAC regimen (5-fluorouracil 600 mg/m² i.v. over 1 h on days 1, 2, 3; doxorubicin 50 mg/m² i.v. bolus on day 1; cyclophosphamide 400 mg/m² i.v. bolus on days 1, 2, 3)
Number of subjects: 258
Study 9652764 — intervention group
Group type: EXPERIMENTAL
Intervention: FULON regimen (5-fluorouracil 250 mg/m² day(-1) continuously infused from day 1 to day 22; doxorubicin 15 mg/m² i.v. bolus on days 1, 8, 15, 22; cyclophosphamide 300 mg/m² i.v. bolus on days 1, 8, 15, 22)
Number of subjects: 258
Study 7661127 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet + Alcohol
Number of subjects: 8
Study 7661127 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet + Placebo
Number of subjects: 8
Study 7661127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet + Alcohol
Number of subjects: 8
Study 7661127 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet + Placebo
Number of subjects: 8
Study 7661127 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol intake
Number of subjects: 8
Study 2667882 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (1 hour, 3 times a week for 8 weeks)
Number of subjects: 99
Study 2667882 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic exercise (1 hour, 3 times a week for 8 weeks)
Number of subjects: 99
Study 2667882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aerobic and nonaerobic exercise
Number of subjects: 99
Study 336135 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction with phenformin (50 mg/day)
Number of subjects: 0
Study 336135 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction without phenformin
Number of subjects: 0
Study 336135 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 0
Study 336135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive treatment
Number of subjects: 0
Study 336135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidaemic treatment (supplemented when necessary)
Number of subjects: 0
Study 29294732 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive-Behavioral Therapy (ICBT) for 20 sessions
Number of subjects: 42
Study 29294732 — intervention group
Group type: COMPARATOR
Intervention: Group Cognitive-Behavioral Therapy (GCBT) for 20 weeks
Number of subjects: 42
Study 29294732 — intervention group
Group type: COMPARATOR
Intervention: Group Cognitive-Behavioral Therapy (GCBT)
Number of subjects: 42
Study 29294732 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive-Behavioral Therapy (ICBT)
Number of subjects: 42
Study 31724347 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 97
Study 31724347 — intervention group
Group type: COMPARATOR
Intervention: Western medication (flunarizine hydrochloride capsule, 5 mg once a day)
Number of subjects: 97
Study 28615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 159
Study 28615506 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 159
Study 25228446 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 70
Study 25228446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23813194 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMPT treatment with TKP cues
Number of subjects: 4
Study 23813194 — intervention group
Group type: COMPARATOR
Intervention: PROMPT treatment without TKP cues
Number of subjects: 4
Study 21477425 — intervention group
Group type: EXPERIMENTAL
Intervention: CDX-947 (solubilized budesonide)
Number of subjects: 173
Study 21477425 — intervention group
Group type: EXPERIMENTAL
Intervention: CDX-313 (solubilized azelastine + budesonide)
Number of subjects: 173
Study 21477425 — intervention group
Group type: COMPARATOR
Intervention: Suspension-type comparators (budesonide [Rhinocort Aqua] or azelastine + budesonide [Astelin] + Rhinocort Aqua)
Number of subjects: 173
Study 21477425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 18648229 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1 mg)
Number of subjects: 16
Study 18648229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 16
Study 18648229 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1 mg) + Ondansetron (4 mg)
Number of subjects: 16
Study 18648229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg oral) administered individually
Number of subjects: 14
Study 17050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2.0 mg oral) administered individually
Number of subjects: 14
Study 17050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of digoxin (1 hour after midazolam)
Number of subjects: 14
Study 15041987 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 61
Study 15041987 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator suburethral tape (T.O.T.)
Number of subjects: 61
Study 10588635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice a day)
Number of subjects: 9
Study 10588635 — intervention group
Group type: EXPERIMENTAL
Intervention: Seratrodast (80 mg once a day)
Number of subjects: 9
Study 10588635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10588635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 9
Study 10588635 — intervention group
Group type: EXPERIMENTAL
Intervention: Seratrodast
Number of subjects: 9
Study 7847430 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose level at 2.2 mmol/L
Number of subjects: 42
Study 7847430 — intervention group
Group type: COMPARATOR
Intervention: Plasma glucose level at 8.9 mmol/L
Number of subjects: 42
Study 7847430 — intervention group
Group type: COMPARATOR
Intervention: Plasma glucose levels (14.4 and 21.1 mmol/L)
Number of subjects: 42
Study 7847430 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 42
Study 7847430 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Men)
Number of subjects: 42
Study 2114625 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic administration of steroids
Number of subjects: 0
Study 2114625 — intervention group
Group type: COMPARATOR
Intervention: Urokinase and no accompanying treatment
Number of subjects: 0
Study 91499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotation of geometric forms
Number of subjects: 32
Study 91499 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial addition of a column of signed digits
Number of subjects: 32
Study 91499 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of letters with subsequent word recognition
Number of subjects: 32
Study 91499 — intervention group
Group type: COMPARATOR
Intervention: Visual fixation
Number of subjects: 32
Study 30696682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib add-on to pre-existing therapy
Number of subjects: 18
Study 28902944 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoelace group (n=35, catheter fixation using shoelace cross-tied sutures)
Number of subjects: 70
Study 28902944 — intervention group
Group type: COMPARATOR
Intervention: Wing group (n=35, catheter fixation with clamping wings and retainers)
Number of subjects: 70
Study 28902944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 23235719 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 111
Study 23235719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 22341199 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 322
Study 22341199 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use reduction
Number of subjects: 322
Study 19398689 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medication reconciliation tool and process redesign
Number of subjects: 322
Study 19398689 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medication reconciliation process)
Number of subjects: 322
Study 19398689 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medication reconciliation tool and process redesign at hospital 1
Number of subjects: 322
Study 19398689 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medication reconciliation tool and process redesign at hospital 2
Number of subjects: 322
Study 17848682 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization treatment
Number of subjects: 36
Study 15976206 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron oral disintegrating tablets (4 mg)
Number of subjects: 62
Study 15976206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12688134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg/day of hGH (biosynthetic human growth hormone‐‐Humatrope)
Number of subjects: 10
Study 12688134 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg/day of hGH (biosynthetic human growth hormone‐‐Humatrope)
Number of subjects: 10
Study 9445311 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrow 'Hands-Off' thermodilution catheter (AHO)
Number of subjects: 150
Study 9445311 — intervention group
Group type: COMPARATOR
Intervention: Standard thermodilution catheter (TC)
Number of subjects: 150
Study 7616301 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (120 mg)
Number of subjects: 0
Study 7616301 — intervention group
Group type: COMPARATOR
Intervention: UV light exposure (three times the minimal erythema dose)
Number of subjects: 0
Study 2377860 — intervention group
Group type: EXPERIMENTAL
Intervention: Soviet diagnostic criteria for osteoarthrosis
Number of subjects: 105
Study 2377860 — intervention group
Group type: EXPERIMENTAL
Intervention: American diagnostic criteria for gonarthrosis
Number of subjects: 105
Study 2377860 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression tree method
Number of subjects: 105
Study 758129 — intervention group
Group type: EXPERIMENTAL
Intervention: RAO/LAO angiography
Number of subjects: 21
Study 758129 — intervention group
Group type: COMPARATOR
Intervention: AP/LAT angiography
Number of subjects: 21
Study 758129 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 21
Study 758129 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-method variability
Number of subjects: 21
Study 31826959 — intervention group
Group type: EXPERIMENTAL
Intervention: Solana HSV 1+2/VZV assay
Number of subjects: 302
Study 31826959 — intervention group
Group type: COMPARATOR
Intervention: Viral culture
Number of subjects: 302
Study 31826959 — intervention group
Group type: EXPERIMENTAL
Intervention: RealStar PCR assay
Number of subjects: 302
Study 30773500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernous tissue–sparing technique
Number of subjects: 92
Study 30773500 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 92
Study 27765728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18113
Study 27765728 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 27765728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 18113
Study 24927225 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized outdoor activity intervention delivered by volunteers (once a week for three months)
Number of subjects: 121
Study 24927225 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 121
Study 24927225 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized outdoor activity intervention (for subgroups with minor depressive symptoms at baseline)
Number of subjects: 121
Study 24490380 — intervention group
Group type: EXPERIMENTAL
Intervention: LVD 100 mg daily
Number of subjects: 58
Study 24490380 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine colligative treatment only)
Number of subjects: 58
Study 21342149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR) solution
Number of subjects: 104
Study 21342149 — intervention group
Group type: COMPARATOR
Intervention: Plasmalyte
Number of subjects: 104
Study 19401375 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning meal size of 418 KJ
Number of subjects: 10
Study 19401375 — intervention group
Group type: COMPARATOR
Intervention: Morning meal size of 2090 KJ
Number of subjects: 10
Study 19401375 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure (2273 to 2361 KJ)
Number of subjects: 10
Study 19401375 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN energy replacement (1521 to 1538 KJ)
Number of subjects: 10
Study 19401375 — intervention group
Group type: EXPERIMENTAL
Intervention: Midday ad libitum meal
Number of subjects: 10
Study 17901191 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education and training program in ethics
Number of subjects: 0
Study 17901191 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17130190 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil-SR (T/V)
Number of subjects: 240
Study 17130190 — intervention group
Group type: COMPARATOR
Intervention: Losartan/Hydrochlorothiazide (L/H)
Number of subjects: 240
Study 12650165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid (ASA) and clopidogrel
Number of subjects: 14330
Study 12650165 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 14330
Study 12650165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA and ticlopidin
Number of subjects: 14330
Study 10390287 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly low-dose vitamin A supplementation (10,000 IU)
Number of subjects: 400
Study 1832824 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 25 micrograms
Number of subjects: 41
Study 1832824 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 40 micrograms
Number of subjects: 41
Study 1832824 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 55 micrograms
Number of subjects: 41
Study 1832824 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 70 micrograms
Number of subjects: 41
Study 6127780 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (beta-adrenoceptor stimulant)
Number of subjects: 27
Study 6127780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28715242 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3)
Number of subjects: 95
Study 28715242 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational psychotherapy (PEP)
Number of subjects: 95
Study 28715242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 95
Study 28715242 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring (AM)
Number of subjects: 95
Study 28709466 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% inhaled hypertonic saline (HS - 4 ml 7% sodium chloride)
Number of subjects: 12
Study 28709466 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS - 0.9% sodium chloride)
Number of subjects: 12
Study 28709466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HS and NS)
Number of subjects: 12
Study 26181507 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (2000 pulses per session, 1-Hz daily for 10 consecutive workdays)
Number of subjects: 70
Study 26181507 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS (2000 pulses per session, 1-Hz daily for 10 consecutive workdays)
Number of subjects: 70
Study 24494287 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle needle
Number of subjects: 95
Study 24494287 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-acupuncture
Number of subjects: 95
Study 24494287 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 95
Study 21392075 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab (0.3, 1, 3, 6 or 10 mg kg(‐1) intravenous infusion)
Number of subjects: 45
Study 21392075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19634955 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (12 sessions, M = 6.2 sessions)
Number of subjects: 353
Study 19634955 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education (WHE) (12 sessions, M = 6.0 sessions)
Number of subjects: 353
Study 17295917 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 4
Study 14686958 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (Kliofem)
Number of subjects: 150
Study 14686958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11136497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d
Number of subjects: 130
Study 11136497 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 200 mg/d
Number of subjects: 130
Study 9576148 — intervention group
Group type: EXPERIMENTAL
Intervention: High-serum-ECP group (serum level of ECP > 15.7 ng/mL)
Number of subjects: 80
Study 9576148 — intervention group
Group type: EXPERIMENTAL
Intervention: High-serum-ECP group
Number of subjects: 80
Study 9576148 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentration of ECP
Number of subjects: 80
Study 7935656 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone, 200 mg orally twice daily for 12 weeks
Number of subjects: 18
Study 7935656 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 18
Study 3229016 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit pectin supplementation
Number of subjects: 27
Study 3229016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30638547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular fibrinolysis (IVF)
Number of subjects: 440
Study 30638547 — intervention group
Group type: COMPARATOR
Intervention: External ventricular drainage (EVD) alone
Number of subjects: 440
Study 28370637 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use negative pressure wound therapy (sNPWT)
Number of subjects: 220
Study 28370637 — intervention group
Group type: COMPARATOR
Intervention: Standard care (film dressings of clinician choice)
Number of subjects: 220
Study 25800762 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (three structured weekly telephone coaching sessions, monthly follow‐up, and a bereavement call)
Number of subjects: 122
Study 25800762 — intervention group
Group type: COMPARATOR
Intervention: Delayed palliative care intervention (three structured weekly telephone coaching sessions, monthly follow‐up, and a bereavement call starting 3 months after enrollment)
Number of subjects: 122
Study 25800762 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (in decedents' CGs)
Number of subjects: 122
Study 25800762 — intervention group
Group type: COMPARATOR
Intervention: Delayed palliative care intervention (in decedents' CGs)
Number of subjects: 122
Study 23699748 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Smart (two classes; N = 51)
Number of subjects: 115
Study 23699748 — intervention group
Group type: COMPARATOR
Intervention: Control (three usual classes; N = 64)
Number of subjects: 115